AKUS Akouos

Akouos to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

Akouos to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

BOSTON, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., CEO, President and co-founder, participated in a pre-recorded fireside chat that will be published today as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference taking place December 1 to 3, 2020.

The fireside chat will be available for on-demand viewing through the investor relations section of Akouos’s website at , beginning today, Monday, November 23, 2020, and will be available for 14 days following the conference.

About Akouos

Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living with disabling hearing loss worldwide. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy.

Contacts

Media:

Katie Engleman, 1AB

Investors:

Courtney Turiano, Stern Investor Relations



EN
23/11/2020

Underlying

AKUSAkouos

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Akouos

 PRESS RELEASE
Free
AKUS AKOUOS

Akouos Reports Third Quarter 2022 Financial Results and Provides Busin...

Akouos Reports Third Quarter 2022 Financial Results and Provides Business Highlights -Received clearance from FDA for the AK-OTOF IND application to initiate a Phase 1/2, first in human, pediatric clinical trial -Continued progress toward planned IND submission for AK-antiVEGF in 2023 -Announced on October 18 definitive agreement for Eli Lilly and Company to acquire Akouos BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss wo...

November 14, 2022 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 42.73
BLUE Bluebird bio I...
RVNC Revance Therape... ... (+25)

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

BLUE BLUEBIRD BIO INC.
RVNC REVANCE THERAPEUTICS INC.
RGNX REGENXBIO INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MCRB SERES THERAPEUTICS
CLFD CLEARFIELD INC.
ARCO ARCOS DORADOS HOLDINGS INC. CLASS A
MXCT MAXCYTE INC
AGYS AGILYSYS INC.
TRNS TRANSCAT
CELC CELCUITY
RCKT ROCKET PHARMACEUTICALS
APLS APELLIS PHARMACEUTICALS
SMID SMITH MIDLAND
GTII GLOBAL TECH INDUSTRIES GROUP I
HROW HARROW HEALTH INC.
AMPY AMPLIFY ENERGY
EVI EVI INDUSTRIES
VTRU VITRU
AKUS AKOUOS
POSH POSHMARK
SMTI SANARA MEDTECH
IMRX IMMUNEERING CORP
CLCL CALCOL INC
KMPH KEMPHARM INC
10/03/22 October 3, 2022 1 EN
 PRESS RELEASE
Free
AKUS AKOUOS

Akouos Receives FDA Clearance of its IND Application for AK-OTOF, a Ge...

Akouos Receives FDA Clearance of its IND Application for AK-OTOF, a Gene Therapy Intended for the Treatment of OTOF-mediated Hearing Loss -The IND for AK-OTOF is the first to receive FDA clearance for a genetic form of hearing loss and the first for an AAV vector therapy with the potential to treat an inner ear condition -Akouos plans to initiate a pediatric Phase 1/2 clinical trial, including children as young as two years of age in the dose-escalation phase (Part A), to evaluate AK-OTOF for the treatment of OTOF-mediated hearing loss -Based on auditory brainstem response data from noncl...

September 13, 2022 1 EN
 PRESS RELEASE
Free
AKUS AKOUOS

Akouos Reports Second Quarter 2022 Financial Results and Provides Busi...

Akouos Reports Second Quarter 2022 Financial Results and Provides Business Highlights Submitted IND for AK-OTOF to FDA Continued progress toward planned IND submission for AK-antiVEGF Presented new nonclinical data at ASGCT supporting the proposed clinical development of AK-OTOF and highlighting strategies for regulated gene expression in the inner ear Received a notice of allowance from USPTO for claims covering compositions, including AK-OTOF, and methods of treatment useful for OTOF-mediated hearing lossEnded Q2 2022 with a strong cash position of $192.9 million BOSTON, Aug. 15, ...

August 15, 2022 1 EN
 PRESS RELEASE
Free
AKUS AKOUOS

Akouos Presents Nonclinical Data Supporting the Planned Clinical Devel...

Akouos Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF and Strategies for Regulated Gene Expression in the Inner Ear at the American Society of Gene and Cell Therapy 25th Annual Meeting - Nonclinical data demonstrate that a single intracochlear administration of an AAVAnc80 vector led to durable restoration of auditory function and was well tolerated, supporting planned clinical development of AK-OTOF for the treatment of OTOF-mediated hearing loss - MicroRNA target site (miR-TS)-incorporation in AAV vectors is shown to have potential benefits for de-target...

May 19, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch